Compare eBay Inc (EBAY) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
eBay Inc vs Gilead Sciences, Inc. — how do they compare? eBay Inc trades at $111.54 (market cap $50.07B), while Gilead Sciences, Inc. trades at $132.91 (market cap $163.51B). The key difference: Gilead Sciences, Inc. is far larger — about 3.3× eBay Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| EBAY | GILD | |
|---|---|---|
Market Cap | $50.07B | $163.51B |
Volume | 5,186,418 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $118.96 | $155.80 |
52-Week Low | $76.79 | $108.22 |
Enterprise Value | $53.41B | $178.05B |
Dividend Yield | 1.1% | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EBAY trades at $111.48, down 0.94% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported revenue of $11.10B in 2025 with a net income margin of 17.61%, and has beaten EPS estimates for three consecutive quarters. Recent news highlights eBay's cleared acquisition of Depop and ongoing takeover interest from GameStop.
EBAY presents a mixed outlook with strong profitability and consistent earnings beats offset by high valuation multiples and competitive pressures. The stock's upside potential hinges on successful integration of acquisitions and advertising growth, while risks include market volatility and execution challenges in a dynamic e-commerce landscape.
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About eBay Inc
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
